Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase.
Mitoxantrone (MH(2)X), an anthraquinone-type anti-cancer agent used clinically in the treatment of human malignancies, is oxidatively activated by the peroxidase/H(2)O(2) enzyme system. In contrast to the enzymatic mechanisms of drug oxidation, the chemical transformations of MH(2)X are not well described. In this study, MH(2)X metabolites, produced by the horseradish, lacto- or lignin peroxidase (respectively HRP, LPO and LIP)/H(2)O(2) system, were investigated by steady-state spectrokinetic and HPLC-MS methods. At an equimolar mitoxantrone/H(2)O(2) ratio, the efficacy of the enzyme-catalyzed oxidation of mitoxantrone decreased in the following order: LPO > HRP > LIP, which accorded with the decreasing size of the substrate access channel in the enzyme panel examined. In all cases, the central drug oxidation product was the redox-active cyclic metabolite, hexahydronaphtho-[2,3-f]-quinoxaline-7,12-dione (MH(2)), previously identified in the urine of mitoxantrone-treated patients. As the reaction progressed, data gathered in this study suggests that further oxidation of the MH(2) side-chains occurred, yielding the mono- and dicarboxylic acid derivatives respectively. Based on the available data a further MH(2) derivative is proposed, in which the amino-alkyl side-chain(s) are cyclised. With increasing H(2)O(2) concentrations, these novel MH(2) derivatives were oxidised to additional metabolites, whose spectral properties and MS data indicated a stepwise destruction of the MH(2) chromophore due to an oxidative cleavage of the 9,10-anthracenedione moiety. The novel metabolites extend the known sequence of peroxidase-induced mitoxantrone metabolism, and may contribute to the cytotoxic effects of the drug in vivo. Based on the structural features of the proposed MH(2) oxidation products we elaborate on various biochemical mechanisms, which extend the understanding of mitoxantrone's pharmaceutical action and its clinical effectiveness with a particular focus on peroxidase-expressing solid tumors, such as breast carcinoma.
Brück
Thomas B
TB
Dept. of Chemistry and Biochemistry, Centre of Excellence in Biomedical and Marine Biotechnology, Florida Atlantic University, 777 Glades Rd., Boca Raton, FL 33431, USA. thomas.brueck@gmail.com
Brück
Dieter W
DW
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D055162:Biocatalysis; D002417:Cattle; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D006735:Horseradish Peroxidase / Q000378:metabolism; D006861:Hydrogen Peroxide / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007784:Lactoperoxidase / Q000378:metabolism; D008942:Mitoxantrone / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D010544:Peroxidases / Q000378:metabolism*; D020075:Phanerochaete / Q000201:enzymology; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D006861:Hydrogen Peroxide; D008942:Mitoxantrone; D006735:Horseradish Peroxidase; D007784:Lactoperoxidase; D010544:Peroxidases; C042858:lignin peroxidase